Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Net Loans Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

DarioHealth (DRIO) Long-Term Debt Repayments (2023 - 2025)

DarioHealth filings provide 2 years of Long-Term Debt Repayments readings, the most recent being $31.5 million for Q2 2025.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $31.5 million in Q2 2025 year-over-year; TTM through Dec 2025 was $31.5 million, a N/A change, with the full-year FY2025 number at $31.5 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $31.5 million in Q2 2025 for DarioHealth, up from $26.4 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $31.5 million in Q2 2025 to a low of $1.4 million in Q1 2023.